Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
AssigneeJanssen Pharmaceutica NV
InventorsAnjali Narayan AVADHANI, Anne Elizabeth O'HAGAN, Ademi Elena SANTIAGO-WALKER
Life of this patent
Estimating the term…
Abstract
Described here are methods of treating urothelial carcinoma in a patient comprising evaluating a biological sample from the patient for the presence of at least two fibroblast growth factor receptor (FGFR) genetic alterations and treating the patient with an FGFR inhibitor. Also described herein are methods of treating urothelial carcinoma in a patient harboring at least two fibroblast growth factor receptor (FGFR) genetic alterations comprising administering a FGFR inhibitor.
Claims24
A method of treating urothelial carcinoma in a patient comprising:
- (a) evaluating a biological sample from the patient for the presence of at least two FGFR genetic alterations, wherein:
- (i) two or more of the at least two FGFR genetic alterations are FGFR2 fusions;
- (ii) one or more of the at least two FGFR genetic alterations is an FGFR2 fusion and one or more of the at least two FGFR genetic alterations is an FGFR3 fusion;
- (iii) two or more of the at least two FGFR genetic alterations are FGFR3 mutations;
- (iv) one or more of the at least two FGFR genetic alterations is an FGFR3 mutation and one or more of the at least two FGFR genetic alterations is an FGFR2 fusion;
- or
- (v) one or more of the at least two FGFR genetic alterations is an FGFR3 mutation and one or more of the at least two FGFR genetic alterations is an FGFR3 fusion;
- and
- (b) treating the patient with an FGFR inhibitor if the at least two FGFR genetic alterations are present in the sample.
A method of treating urothelial carcinoma in a patient harboring at least two FGFR genetic alterations comprising administering a FGFR inhibitor to the patient, wherein:
- (a) two or more of the at least two FGFR genetic alterations are FGFR2 fusions;
- (b) one or more of the at least two FGFR genetic alterations is an FGFR2 fusion and one or more of the at least two FGFR genetic alterations is an FGFR3 fusion;
- (c) two or more of the at least two FGFR genetic alterations are FGFR3 mutations;
- (d) one or more of the at least two FGFR genetic alterations is an FGFR3 mutation and one or more of the at least two FGFR genetic alterations is an FGFR2 fusion;
- or
- (e) one or more of the at least two FGFR genetic alterations is an FGFR3 mutation and one or more of the at least two FGFR genetic alterations is an FGFR3 fusion.
24-31. canceled
Dependencies are inferred from the claim text.